Posted on Wed, 05 Feb 2020 14:38:00 GMT By Admin
We are excited to announce that our portfolio of allergens has increased to 67. The allergen portfolio now includes the first screening mix to help in the diagnosis of grass allergies. Hazelnut and Almond, two important nut allergens, have been added to our common allergen list. rPen a 1 and rOle e 1, two new allergen molecules, have also been added to complement the allergy range, which aims to comprise the most prominent and clinically relevant allergens.
Read more about our new allergen releases and their relevance at our partner's website: https://www.idsplc.com/company-news/expanding-allergy/
Posted on Tue, 20 Aug 2019 10:19:00 GMT By Admin
We are excited to announce that we have received our first purchase order for 20,000 units of its VISITECT® CD4 Advanced Disease test from our partner company in Zimbabwe. Whilst the VISITECT® CD4 Advanced Disease test is currently undergoing review by the UNITAID-funded Expert Review Panel for Diagnostics (ERPD), the order from Zimbabwe is not contingent upon conclusion of the ERPD process as this order will supply into B2B marketing channels, rather than NGOs.
Read the full announcement here
Posted on Mon, 19 Aug 2019 10:35:00 GMT By Admin
We are pleased to announce that we have received a purchase order from our distributor in Nigeria for 50,000 units of VISITECT® CD4. This order is conditional upon the Nigerian Ministry of Health approving the VISITECT® CD4 into its national HIV policy, a process which is ongoing.
Posted on Mon, 12 Aug 2019 10:27:00 GMT By Admin
We have successfully CE marked two additional allergens for the allergy range, increasing the allergy menu to 62 allergens that can
be run on the IDS automated instrument.
- Pistachio (F203)
- nGal d 1 (F233)
Posted on Mon, 18 Mar 2019 08:43:00 GMT By Admin
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has CE-Marked its VISITECT® CD4 Advanced Disease test for monitoring people living with HIV.
The VISITECT® CD4 Advanced Disease test utilises a cut-off of 200 CD4 cells/mm³ of blood, a level at which patients’ immune systems are so weakened by HIV that they are at risk of infection by other life-threatening diseases.
The technical file supporting the CE-Mark will form the basis of the additional regulatory approvals that the Company will seek through the UNITAID-funded Expert Review Panel for Diagnostics (“ERPD”), hosted by the Global Fund to Fight AIDS, Tuberculosis and Malaria. The ERPD outcome is a time-limited, risk-based recommendation on eligibility for procurement whilst the Company undergoes the World Health Organisation Prequalification programme. This programme aims to ensure that clinical diagnostics, medicines and vaccines meet global ...
Posted on Wed, 06 Mar 2019 08:49:00 GMT By Admin
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has received its first purchase orders for its VISITECT® CD4 350 cut-off test and continues to make progress with its VISITECT® CD4 Advanced Disease test.
VISITECT® CD4 350 cut-off test
The Company is pleased to report that it has received its first purchase orders for its CE-Marked VISITECT® CD4 350 cut-off test from distributors supplying into Indonesia, Moldova and Papua New Guinea. As expected by the Company, the order quantities are low at this stage and reflect distributors’ intentions to seed their private business-to-business market channels in the initial stages. Nevertheless, this is an endorsement of the Company’s ability to develop and then commercialise this product through the regulatory processes in international markets. We expect to supply customers before the end of the current financial year.
As previously indicated, we see Niger ...
Posted on Fri, 01 Mar 2019 09:27:00 GMT By Admin
OMEGA DIAGNOSTICS GROUP PLC
(“Omega” or the “Company” or the “Group”)
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the appointment of Jeremy Millard as Non-Executive Director to the Board with immediate effect, after a thorough search process.
The Board consider Jeremy to be independent and it is anticipated that he will, in due course, be appointed to the Audit and Remuneration Committees of the Company.
Jeremy has 20 years investment banking experience and was previously a partner at Smith Square Partners LLP where he provided strategic and corporate advice to clients in the science, technology and telecommunications sectors, prior to which he headed up the technology practice at Rothschild in London. Jeremy is currently a Non-Executive Director and chairman of the audit committee of AIM-listed Idox plc and a Non-Executive Director of AIM-listed Ilika Plc.
Bill Rhodes, Interim Non ...
Posted on Thu, 10 May 2018 16:28:00 GMT By Admin
Omega announces that it has signed a global distribuon agreement with Immunodiagnostic Systems Limited for its Allersys® range of allergy assays.
Click here to read the full article.
Posted on Fri, 01 Dec 2017 13:26:00 GMT By Admin
Omega Diagnostics, the medical diagnostics company focused on allergy, food intolerance and infectious disease, is delighted to announce it has successfully achieved CE-Marking of its VISITECT® CD4 test for supporting the management of people living with HIV, following successful performance evaluations in India and the UK.
VISITECT® CD4, co-developed with the Burnet Institute, is the world’s first instrument-free and affordable rapid test for determining CD4 threshold in people living with HIV. It is designed for use at the point-of-care and provides a means for decentralisation of CD4 testing capacity to where it is most needed. VISITECT® CD4 will enable those patients in rural locations to access testing more easily and does not require investment in equipment or highly technical scientific staff to operate. The test will now go forward into further regulatory processes that are necessary before being implemented in those regions where HIV remains a significant public health chall ...